# A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors

> **NCT06433726** · PHASE1 · RECRUITING · sponsor: **Chengdu Baiyu Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** BY101921 tablets

## Key facts

- **NCT ID:** NCT06433726
- **Lead sponsor:** Chengdu Baiyu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433726, "A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06433726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*